Exact Mass: 827.7005626
Exact Mass Matches: 827.7005626
Found 500 metabolites which its exact mass value is equals to given mass value 827.7005626,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PC(22:0/P-18:1(11Z))
C48H94NO7P (827.6767543999999)
PC(22:0/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:0/P-18:1(11Z)), in particular, consists of one chain of behenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The behenic acid moiety is derived from groundnut oil, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(22:0/P-18:1(9Z))
C48H94NO7P (827.6767543999999)
PC(22:0/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:0/P-18:1(9Z)), in particular, consists of one chain of behenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The behenic acid moiety is derived from groundnut oil, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(22:1(13Z)/P-18:0)
C48H94NO7P (827.6767543999999)
PC(22:1(13Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:1(13Z)/P-18:0), in particular, consists of one chain of erucic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The erucic acid moiety is derived from seed oils and avocados, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(24:1(15Z)/P-16:0)
C48H94NO7P (827.6767543999999)
PC(24:1(15Z)/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(24:1(15Z)/P-16:0), in particular, consists of one chain of nervonic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The nervonic acid moiety is derived from fish oils, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-16:0/24:1(15Z))
C48H94NO7P (827.6767543999999)
PC(P-16:0/24:1(15Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/24:1(15Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of nervonic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the nervonic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-18:0/22:1(13Z))
C48H94NO7P (827.6767543999999)
PC(P-18:0/22:1(13Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/22:1(13Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of erucic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the erucic acid moiety is derived from seed oils and avocados. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-18:1(11Z)/22:0)
C48H94NO7P (827.6767543999999)
PC(P-18:1(11Z)/22:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/22:0), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of behenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the behenic acid moiety is derived from groundnut oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-18:1(9Z)/22:0)
C48H94NO7P (827.6767543999999)
PC(P-18:1(9Z)/22:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/22:0), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of behenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the behenic acid moiety is derived from groundnut oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(O-18:2(9Z,12Z)/22:0)
C48H94NO7P (827.6767543999999)
PC(O-18:2(9Z,12Z)/22:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(O-18:2(9Z,12Z)/22:0), in particular, consists of one chain of Linoleyl alcohol at the C-1 position and one chain of behenic acid at the C-2 position. The Linoleyl alcohol moiety is derived from seed oils, while the behenic acid moiety is derived from groundnut oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(o-18:2(9Z,12Z)/22:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(o-18:2(9Z,12Z)/22:0), in particular, consists of one chain of Linoleyl alcohol at the C-1 position and one chain of behenic acid at the C-2 position. The Linoleyl alcohol moiety is derived from seed oils, while the behenic acid moiety is derived from groundnut oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
galactocerebrosides
Lecithin
C48H94NO7P (827.6767543999999)
PC(O-18:0/22:2(13Z,16Z))
C48H94NO7P (827.6767543999999)
PC(O-20:0/20:2(11Z,14Z))
C48H94NO7P (827.6767543999999)
PC(P-18:0/22:1(11Z))
C48H94NO7P (827.6767543999999)
PC(P-20:0/20:1(11Z))
C48H94NO7P (827.6767543999999)
PC O-40:2
C48H94NO7P (827.6767543999999)
HexCer 42:1;O3
N-(2-hydroxypentacosanoyl)-1-O-beta-D-glucosyl-15-methylhexadecasphing-4-enine
(2S)-N-[(1S,2R,3E)-1-[(beta-D-Galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecenyl]-2-hydroxytetracosanamide
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(Z)-tetracos-15-enoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
(15z)-N-[(2s,3s,4r)-1-(Alpha-D-Galactopyranosyloxy)-3,4-Dihydroxyoctadecan-2-Yl]tetracos-15-Enamide
2-[hydroxy-[(2S,3R,4E,14Z)-3-hydroxy-2-(pentacosanoylamino)octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(2S,3R)-3-hydroxy-2-(pentacos-3-enoylamino)octadec-5-enoxy]phosphoryl]oxyethyl-trimethylazanium
[3-dodecoxy-2-[(17Z,20Z)-octacosa-17,20-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-N-[(4E,8E,12E)-1,3-dihydroxytriaconta-4,8,12-trien-2-yl]hexacosa-5,8,11,14,17,20,23-heptaenamide
(17Z,20Z,23Z,26Z,29Z,32Z,35Z,38Z,41Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]tetratetraconta-17,20,23,26,29,32,35,38,41-nonaenamide
(12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]hexatriaconta-12,15,18,21,24,27,30,33-octaenamide
(20Z,23Z,26Z,29Z,32Z,35Z,38Z,41Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]tetratetraconta-20,23,26,29,32,35,38,41-octaenamide
(15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E,12E)-1,3-dihydroxyicosa-4,8,12-trien-2-yl]hexatriaconta-15,18,21,24,27,30,33-heptaenamide
(11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E,12E)-1,3-dihydroxytetracosa-4,8,12-trien-2-yl]dotriaconta-11,14,17,20,23,26,29-heptaenamide
(15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]dotetraconta-15,18,21,24,27,30,33,36,39-nonaenamide
(11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(E)-1,3-dihydroxyoctadec-4-en-2-yl]octatriaconta-11,14,17,20,23,26,29,32,35-nonaenamide
(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]tetratriaconta-10,13,16,19,22,25,28,31-octaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexacosa-4,8,12-trien-2-yl]triaconta-9,12,15,18,21,24,27-heptaenamide
(19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]tetraconta-19,22,25,28,31,34,37-heptaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(E)-1,3-dihydroxyicos-4-en-2-yl]hexatriaconta-9,12,15,18,21,24,27,30,33-nonaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(E)-1,3-dihydroxydocos-4-en-2-yl]tetratriaconta-7,10,13,16,19,22,25,28,31-nonaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E)-1,3-dihydroxytetracosa-4,8-dien-2-yl]dotriaconta-8,11,14,17,20,23,26,29-octaenamide
(18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]dotetraconta-18,21,24,27,30,33,36,39-octaenamide
(14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]octatriaconta-14,17,20,23,26,29,32,35-octaenamide
(16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]tetraconta-16,19,22,25,28,31,34,37-octaenamide
(13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]tetraconta-13,16,19,22,25,28,31,34,37-nonaenamide
(17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(4E,8E,12E)-1,3-dihydroxyoctadeca-4,8,12-trien-2-yl]octatriaconta-17,20,23,26,29,32,35-heptaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-N-[(4E,8E,12E)-1,3-dihydroxyoctacosa-4,8,12-trien-2-yl]octacosa-7,10,13,16,19,22,25-heptaenamide
(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(E)-1,3-dihydroxytetracos-4-en-2-yl]dotriaconta-5,8,11,14,17,20,23,26,29-nonaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[(4E,8E)-1,3-dihydroxyhexacosa-4,8-dien-2-yl]triaconta-6,9,12,15,18,21,24,27-octaenamide
(21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]dotetraconta-21,24,27,30,33,36,39-heptaenamide
(13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E,12E)-1,3-dihydroxydocosa-4,8,12-trien-2-yl]tetratriaconta-13,16,19,22,25,28,31-heptaenamide
(14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z,38Z,41Z)-N-(1,3-dihydroxydodecan-2-yl)tetratetraconta-14,17,20,23,26,29,32,35,38,41-decaenamide
(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-(1,3-dihydroxyhexadecan-2-yl)tetraconta-10,13,16,19,22,25,28,31,34,37-decaenamide
(12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-(1,3-dihydroxytetradecan-2-yl)dotetraconta-12,15,18,21,24,27,30,33,36,39-decaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-(1,3-dihydroxyicosan-2-yl)hexatriaconta-6,9,12,15,18,21,24,27,30,33-decaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-(1,3-dihydroxyoctadecan-2-yl)octatriaconta-8,11,14,17,20,23,26,29,32,35-decaenamide
(E)-3-hydroxy-2-(2-hydroxyhexacosanoylamino)tricos-4-ene-1-sulfonic acid
C49H97NO6S (827.7036221999999)
3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]hexacosane-1-sulfonic acid
C49H97NO6S (827.7036221999999)
3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]tetracosane-1-sulfonic acid
C49H97NO6S (827.7036221999999)
3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]pentacosane-1-sulfonic acid
C49H97NO6S (827.7036221999999)
(E)-3-hydroxy-2-(2-hydroxytricosanoylamino)hexacos-4-ene-1-sulfonic acid
C49H97NO6S (827.7036221999999)
(E)-3-hydroxy-2-(2-hydroxytetracosanoylamino)pentacos-4-ene-1-sulfonic acid
C49H97NO6S (827.7036221999999)
3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]tricosane-1-sulfonic acid
C49H97NO6S (827.7036221999999)
(E)-3-hydroxy-2-(2-hydroxypentacosanoylamino)tetracos-4-ene-1-sulfonic acid
C49H97NO6S (827.7036221999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] (Z)-octacos-17-enoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] tetracosanoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] (Z)-tetracos-13-enoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] (17Z,20Z)-octacosa-17,20-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentacosoxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexacosoxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] tricosanoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] henicosanoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-henicosoxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-docosoxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-docos-13-enoxy]propan-2-yl] (Z)-henicos-11-enoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonadecoxypropan-2-yl] (13Z,16Z)-tetracosa-13,16-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-henicos-11-enoxy]propan-2-yl] (Z)-docos-13-enoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptacosoxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexacos-15-enoxy]propan-2-yl] (Z)-heptadec-9-enoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] (Z)-hexacos-15-enoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetracosoxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] docosanoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] (15Z,18Z)-hexacosa-15,18-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(17Z,20Z)-octacosa-17,20-dienoxy]propan-2-yl] pentadecanoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-tetracosa-13,16-dienoxy]propan-2-yl] nonadecanoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetracos-13-enoxy]propan-2-yl] (Z)-nonadec-9-enoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octacos-17-enoxy]propan-2-yl] (Z)-pentadec-9-enoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tricosoxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(15Z,18Z)-hexacosa-15,18-dienoxy]propan-2-yl] heptadecanoate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] hexacosanoate
C48H94NO7P (827.6767543999999)
[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-nonadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(Z)-henicos-11-enoxy]-2-[(Z)-nonadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(Z)-icos-11-enoxy]-2-[(Z)-icos-11-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(13Z,16Z)-docosa-13,16-dienoxy]-2-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(11Z,14Z)-icosa-11,14-dienoxy]-2-icosanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-docosoxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(Z)-docos-13-enoxy]-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-tetracosoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(11Z,14Z)-henicosa-11,14-dienoxy]-2-nonadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-tricosoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(15Z,18Z)-hexacosa-15,18-dienoxy]-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-henicosanoyloxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-[(Z)-henicos-11-enoyl]oxy-3-[(Z)-nonadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-tricosanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-icosoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-dodecanoyloxy-3-[(17Z,20Z)-octacosa-17,20-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-henicosoxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-hexadecanoyloxy-3-[(13Z,16Z)-tetracosa-13,16-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(Z)-hexacos-15-enoxy]-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-[(Z)-hexadec-9-enoyl]oxy-3-[(Z)-tetracos-13-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
2-[4-(3-hexacosanoyloxy-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]acetic acid
[3-hexadecoxy-2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] heptacosanoate
C48H94NO7P (827.6767543999999)
[2-docosanoyloxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-[(Z)-hexacos-15-enoyl]oxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-tetracosanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-3-tetradecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-octadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[3-[(Z)-hexadec-9-enoxy]-2-[(Z)-tetracos-13-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] pentacosanoate
C48H94NO7P (827.6767543999999)
[2-[(Z)-docos-13-enoyl]oxy-3-[(Z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
[(2R)-3-[(E)-icos-1-enoxy]-2-[(E)-icos-11-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-(tetracosanoylamino)nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(E)-tetracos-15-enoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocosan-2-yl]henicosanamide
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-(pentacosanoylamino)octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosan-2-yl]tricosanamide
2-[[(E,2S,3R)-2-[[(E)-hexacos-17-enoyl]amino]-3-hydroxyheptadec-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(E)-tetracos-15-enoyl]amino]nonadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosan-2-yl]docosanamide
2-[[(E,2S,3R)-2-[[(E)-docos-13-enoyl]amino]-3-hydroxyhenicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2S,3R,4E,8E)-2-(hexacosanoylamino)-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(2R)-2-[(E)-docos-13-enoyl]oxy-3-[(E)-octadec-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
2-[[(E,2S,3R)-2-[[(E)-hexacos-17-enoyl]amino]-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(2R)-3-[(E)-hexadec-1-enoxy]-2-[(E)-tetracos-15-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
2-[hydroxy-[(2S,3R,4E,14E)-3-hydroxy-2-(pentacosanoylamino)octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E,2S,3R)-2-[[(E)-docos-13-enoyl]amino]-3-hydroxyhenicos-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadecan-2-yl]hexacosanamide
N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]pentacosanamide
[(2R)-3-[(E)-icos-1-enoxy]-2-[(E)-icos-13-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C48H94NO7P (827.6767543999999)
N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadecan-2-yl]tetracosanamide
2-[[(2S,3R,4E,8E)-2-(henicosanoylamino)-3-hydroxydocosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-(tricosanoylamino)icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(2S,3R,4E,8E)-2-(docosanoylamino)-3-hydroxyhenicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-hexacos-11-enoyl]amino]-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(13Z,16Z)-octacosa-13,16-dienoyl]amino]pentadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(nonadecanoylamino)tetracosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(tetracosanoylamino)nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]octacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-nonacos-14-enoyl]amino]tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]nonacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(tetradecanoylamino)nonacosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octadecanoylamino)pentacosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(icosanoylamino)tricosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(hexadecanoylamino)-3-hydroxyheptacosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentacosanoylamino)octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(heptacosanoylamino)-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(tridecanoylamino)triaconta-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-heptacos-12-enoyl]amino]-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(11Z,14Z)-hexacosa-11,14-dienoyl]amino]-3-hydroxyheptadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]tricos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tetracos-11-enoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-henicos-9-enoyl]amino]-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(heptadecanoylamino)-3-hydroxyhexacosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxyheptacosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(hexacosanoylamino)-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tricos-11-enoyl]amino]icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxyhenicosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octacosanoylamino)pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-docos-11-enoyl]amino]-3-hydroxyhenicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-pentacos-11-enoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]pentacosoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentadecanoylamino)octacosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(nonacosanoylamino)tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]tetracos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]tricosoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxyheptacos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]pentacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(henicosanoylamino)-3-hydroxydocosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-octacos-13-enoyl]amino]pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(tricosanoylamino)icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(18Z,21Z)-tetracosa-18,21-dienoyl]amino]nonadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(docosanoylamino)-3-hydroxyhenicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]triacont-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxyhenicosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxyheptatriaconta-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(decanoylamino)-3-hydroxytritriaconta-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(nonanoylamino)tetratriaconta-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-triacont-19-enoyl]amino]tridec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxydocosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-octacos-17-enoyl]amino]pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxyheptadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(23Z,26Z)-tetratriaconta-23,26-dienoyl]amino]nonoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxyhexacos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]nonadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxyhenicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(dodecanoylamino)-3-hydroxyhentriaconta-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]triacont-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(21Z,24Z)-dotriaconta-21,24-dienoyl]amino]-3-hydroxyundecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(17Z,20Z)-octacosa-17,20-dienoyl]amino]pentadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(19Z,22Z)-triaconta-19,22-dienoyl]amino]tridecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyheptacosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxyhexacosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octanoylamino)pentatriaconta-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(hentriacontanoylamino)-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]pentacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]tetracosoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]pentacosoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(triacontanoylamino)trideca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tetratriacont-23-enoyl]amino]non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyheptacos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxyhexatriaconta-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(Z)-dotriacont-21-enoyl]amino]-3-hydroxyundec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(undecanoylamino)dotriaconta-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
1-(beta-D-galactosyl)-N-[(2R)-2-hydroxylignoceroyl]sphingosine
A D-galactosyl-N-acylsphingosine in which the ceramide N-acyl group is specified as (R)-2-hydroxylignoceroyl.
1-O-(alpha-D-galactosyl)-N-[(15Z)-tetracos-15-enoyl]phytosphingosine
A glycophytoceramide that consists of phytosphingosine having an alpha-D-galactosyl attached at the O-1 position via a glycosidic linkage and a (Z)-tetracos-15-enoyl group attached to the nitrogen.
phosphatidylcholine O-40:2
C48H94NO7P (827.6767543999999)
An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 40 carbons and 2 double bonds.
1-octadecyl-2-[(13Z,16Z)-docosadienoyl]-sn-glycero-3-phosphocholine
C48H94NO7P (827.6767543999999)
A phosphatidylcholine O-40:2 in which the alkyl and acyl groups at positions 1 and 2 are octadecyl and (13Z,16Z)-docosadienoyl respectively.
Hex1Cer(42:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(39:2)
C48H94NO7P (827.6767543999999)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(43:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved